{
  "chunk_id": "V_iii_9_None_16",
  "content": "/>\nV.iii.9.2.b\n.\nReview Examinations of NHL and Other Persistent Cancers\nWhen evaluating the need for a review examination at the two-year period prescribed in the rating schedule under\n38 CFR 4.117, DC 7715\n, following discontinuance of the treatment phase for non-Hodgkin’s lymphoma (NHL) or any other persistent cancer with a high mortality rate, consider that the various therapeutic treatment modalities may continue at intervals greater than the review period indicated in the rating schedule.\nIf the disease has actively persisted for several years, thoroughly examine the medical record to determine whether the disease is\nactually in remission, or\nstill active and being regularly treated over extended periods of time.\nDo\nnot\nschedule a review examination unless the record clearly shows a long-term and stable remission.\nImportant\n:  Consider assigning a P&T evaluation when a provision under\n38 CFR 3.327(b)(2)\napplies or as otherwise warranted under the provisions of\nM21-1, Part V, Subpart ii, 3.D.4\n.\nReference\n:  For more information on when not to schedule a review examination, see\nM21-1, Part IV, Subpart i, 2.G\n.",
  "title": "M21-1, Part V, Subpart iii, Chapter 9 - Hematologic and Lymphatic Systems",
  "citation": "Part V, Subpart iii, Chapter 9, Section None",
  "source_url": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180513/M21-1-Part-V-Subpart-iii-Chapter-9-Hematologic-and-Lymphatic-Systems",
  "updated": "",
  "scraped_at": "2025-06-16T22:45:35.239285",
  "tags": [
    "m21-1"
  ]
}